Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed No phase listed Observational Results available

A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

ClinicalTrials.gov ID: NCT00759174

Public ClinicalTrials.gov record NCT00759174. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this non-interventional study is to examine whether use of Phosphodiesterase Inhibitors (PDE5s), including use of sildenafil, vardenafil, or tadalafil, triggers the onset of acute NAION.

Study identification

NCT ID
NCT00759174
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Enrollment
673 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
45 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2008
Primary completion
Sep 30, 2012
Completion
Sep 30, 2012
Last update posted
Jan 31, 2021

2008 – 2012

United States locations

U.S. sites
69
U.S. states
32
U.S. cities
60
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35294 —
Pfizer Investigational Site Mobile Alabama 36606 —
Pfizer Investigational Site Anchorage Alaska 99501 —
Pfizer Investigational Site Little Rock Arkansas 72205-7199 —
Pfizer Investigational Site Little Rock Arkansas 72212 —
Pfizer Investigational Site Loma Linda California 92354 —
Pfizer Investigational Site Long Beach California 90813 —
Pfizer Investigational Site Los Angeles California 90033 —
Pfizer Investigational Site Los Angeles California 90095 —
Pfizer Investigational Site Oceanside California 92056 —
Pfizer Investigational Site Pasadena California 91105 —
Pfizer Investigational Site Aurora Colorado 80045 —
Pfizer Investigational Site New Haven Connecticut 06510 —
Pfizer Investigational Site Southbury Connecticut 06488 —
Pfizer Investigational Site Waterbury Connecticut 06708 —
Pfizer Investigational Site Washington D.C. District of Columbia 20007 —
Pfizer Investigational Site Washington D.C. District of Columbia 20037 —
Pfizer Investigational Site Bradenton Florida 34208 —
Pfizer Investigational Site Miami Florida 33136 —
Pfizer Investigational Site Tampa Florida 33612 —
Pfizer Investigational Site Atlanta Georgia 30322 —
Pfizer Investigational Site Augusta Georgia 30909 —
Pfizer Investigational Site Lisle Illinois 60532 —
Pfizer Investigational Site Dubuque Iowa 52002 —
Pfizer Investigational Site Prairie Village Kansas 66208 —
Pfizer Investigational Site Lafayette Louisiana 70503 —
Pfizer Investigational Site Lafayette Louisiana 70506 —
Pfizer Investigational Site Ruston Louisiana 71270 —
Pfizer Investigational Site Baltimore Maryland 21204 —
Pfizer Investigational Site Baltimore Maryland 21287 —
Pfizer Investigational Site Beverly Massachusetts 01915 —
Pfizer Investigational Site Boston Massachusetts 02114 —
Pfizer Investigational Site North Dartmouth Massachusetts 02747 —
Pfizer Investigational Site Ann Arbor Michigan 48105 —
Pfizer Investigational Site Detroit Michigan 48202 —
Pfizer Investigational Site Minneapolis Minnesota 55455 —
Pfizer Investigational Site St Louis Missouri 63104 —
Pfizer Investigational Site Omaha Nebraska 68198 —
Pfizer Investigational Site Reno Nevada 89502 —
Pfizer Investigational Site Lebanon New Hampshire 03756 —
Pfizer Investigational Site Manchester New Hampshire 03104 —
Pfizer Investigational Site Chester New Jersey 07930 —
Pfizer Investigational Site Newark New Jersey 07103 —
Pfizer Investigational Site Roseland New Jersey 07068 —
Pfizer Investigational Site Teaneck New Jersey 07666 —
Pfizer Investigational Site Latham New York 12110 —
Pfizer Investigational Site Rochester New York 14642 —
Pfizer Investigational Site Stony Brook New York 11794 —
Pfizer Investigational Site Troy New York 12180 —
Pfizer Investigational Site Woodbury New York 11788 —
Pfizer Investigational Site Durham North Carolina 27705 —
Pfizer Investigational Site Cincinnati Ohio 45242 —
Pfizer Investigational Site Columbus Ohio 43215 —
Pfizer Investigational Site Portland Oregon 97239 —
Pfizer Investigational Site Lancaster Pennsylvania 17602 —
Pfizer Investigational Site Philadelphia Pennsylvania 19104 —
Pfizer Investigational Site Philadelphia Pennsylvania 19107 —
Pfizer Investigational Site Philadelphia Pennsylvania 19114 —
Pfizer Investigational Site Pittsburgh Pennsylvania 15212 —
Pfizer Investigational Site Charleston South Carolina 29425 —
Pfizer Investigational Site Greenville South Carolina 29615 —
Pfizer Investigational Site Spartanburg South Carolina 29302 —
Pfizer Investigational Site Spartanburg South Carolina 29306 —
Pfizer Investigational Site Austin Texas 78705 —
Pfizer Investigational Site Houston Texas 77030 —
Pfizer Investigational Site Salt Lake City Utah 84132 —
Pfizer Investigational Site Richmond Virginia 23226 —
Pfizer Investigational Site Richmond Virginia 23298 —
Pfizer Investigational Site Seattle Washington 98104 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00759174, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 31, 2021 · Synced Sep 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00759174 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →